New Clinical trial to see of Cabo will trump Sutent. This is great.
Cabozanitinub is going to start studies to see if it will become a FIRST IN LINE drug for kidney cancer.
This means that there could be a drug to come out ahead of the one already prescribed first, Sutent.
I think the article says a Phase 3 trial is going to start of the drug.
http://www.fool.com/investing/2016/05/27/this-new-data-could-push-exelixis-cabometyx-over-1.aspx
This means we are getting another drug that will likely prolong survival.
Comments
-
another drug
I don't remember what drug I was getting that I was told " There is'nt anything after this." I do remember that it wasn't that long ago. And here we are with new stuff to try faster than I can burn through what I am taking. So, how many shares of drug company do I need to break even with treatment from said company?? Thanks for the link sblairc!!
Bobby
0
Discussion Boards
- All Discussion Boards
- 6 CSN Information
- 6 Welcome to CSN
- 121.9K Cancer specific
- 2.8K Anal Cancer
- 446 Bladder Cancer
- 309 Bone Cancers
- 1.6K Brain Cancer
- 28.5K Breast Cancer
- 398 Childhood Cancers
- 27.9K Colorectal Cancer
- 4.6K Esophageal Cancer
- 1.2K Gynecological Cancers (other than ovarian and uterine)
- 13K Head and Neck Cancer
- 6.4K Kidney Cancer
- 671 Leukemia
- 794 Liver Cancer
- 4.1K Lung Cancer
- 5.1K Lymphoma (Hodgkin and Non-Hodgkin)
- 237 Multiple Myeloma
- 7.1K Ovarian Cancer
- 63 Pancreatic Cancer
- 487 Peritoneal Cancer
- 5.5K Prostate Cancer
- 1.2K Rare and Other Cancers
- 540 Sarcoma
- 734 Skin Cancer
- 653 Stomach Cancer
- 191 Testicular Cancer
- 1.5K Thyroid Cancer
- 5.9K Uterine/Endometrial Cancer
- 6.3K Lifestyle Discussion Boards